Work

Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial

Year: 2019

Type: erratum

Abstract: The following error appeared in the corrected proof publication of this article [File TM, Goldberg L, Das A, et al. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. Clin Infect Dis https://doi.org/10.1093/cid/ciz090]: In the acknowledgement section, it currently states “G. H. T. is currently a member of the Board of Directors of Nabriva Therapeutics and has received personal fees and/or other support from Actelion, Adynxx, AN2 Therapeutics, Calixa Therapeutics, Meiji-Seika, Nabriva Therapeutics, Recida Therapeutics, Tripex, and Zavante Therapeutics, outside the submitted work, and payments, non-financial support, and other from BioMarkers Consortium of the FNIH, during the conduct of the study.” The correct acknowledgement should state “G. H. T. is currently a member of the Board of Directors of Nabriva Therapeutics and has received personal fees and/or other support from Actelion, Adynxx, AN2 Therapeutics, Calixa Therapeutics, Meiji-Seika, Nabriva Therapeutics, Recida Therapeutics, Tripex, and Zavante Therapeutics, outside the submitted work.” The publisher regrets this error.

Source: Clinical Infectious Diseases

DOI: 10.1093/cid/ciz710